Stocktoria
BeOne Medicines Ltd. ONC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-03-02
BeOne Medicines Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B | $1.2B |
| Gross profit | $4.7B | $3.2B | $2.1B | $1.1B | $1.0B |
| R&D expense | $2.1B | $2.0B | $1.8B | $1.6B | $1.5B |
| SG&A expense | $2.1B | $1.8B | $1.5B | $1.3B | $990.1M |
| Operating income | $447.1M | -$568.2M | -$1.2B | -$1.8B | -$1.4B |
| Income tax | $129.9M | $111.8M | $55.9M | $42.8M | $19.2M |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2.0B | -$1.5B |
| EPS (diluted) | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 |
| Operating cash flow | $1.1B | -$140.6M | -$1.2B | -$1.5B | -$1.3B |
| Free cash flow | $941.7M | -$633.3M | -$1.7B | -$1.8B | -$1.6B |
| Cash & equivalents | $4.5B | $2.6B | $3.2B | $3.9B | $4.4B |
| Inventory | $608.2M | $495.0M | $416.1M | $282.3M | $242.6M |
| Total assets | $8.2B | $5.9B | $5.8B | $6.4B | $8.5B |
| Total liabilities | $3.8B | $2.6B | $2.3B | $2.0B | $2.4B |
| Shareholders' equity | $4.4B | $3.3B | $3.5B | $4.4B | $6.1B |
Source: SEC EDGAR filings · CIK 0001651308 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.